FCCC LOGO Faculty Publications
Maifrede S , Martinez E , Nieborowska-Skorska M , Di Marcantonio D , Hulse M , Le BV , Zhao H , Piwocka K , Tempera I , Sykes SM , Skorski T
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs
Blood Adv. 2017 Aug 22;1(19) :1467-1472
PMID: 29296788    PMCID: PMC5728460 interests.   
Back to previous list
PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.
Maifrede, Silvia Martinez, Esteban Nieborowska-Skorska, Margaret Di Marcantonio, Daniela Hulse, Michael Le, Bac Viet Zhao, Huaqing Piwocka, Katarzyna Tempera, Italo Sykes, Stephen M Skorski, Tomasz R00 CA158461/CA/NCI NIH HHS/United States R01 CA134458/CA/NCI NIH HHS/United States R01 CA186238/CA/NCI NIH HHS/United States Journal Article United States Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22.